Galectin-3 and Placenta Accreta
The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta
1 other identifier
observational
62
1 country
1
Brief Summary
Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell. They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues. Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis. Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 28, 2020
CompletedStudy Start
First participant enrolled
October 1, 2020
CompletedFirst Posted
Study publicly available on registry
October 5, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2021
CompletedOctober 10, 2022
October 1, 2022
1 year
September 28, 2020
October 7, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Galactin 3 level in the blood
measured by ng/ml
6 weeks
Study Arms (2)
Normal pregnancy group
Placenta accreta at 24-32 weeks group
Interventions
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
Eligibility Criteria
Pregnant women
You may qualify if:
- Pregnant women between 28-32 weeks.
- Age between 20-40 years.
- Singleton pregnancy.
- Women with suspicion of placenta accreta
- Cases with mild vaginal bleeding or not having any vaginal bleeding.
You may not qualify if:
- Women are known to have any medical disorders.
- Patients with known bleeding disorders or on anticoagulant therapy.
- Patients refuse to participate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Women Health Hospital - Assiut university
Asyut, 71111, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
September 28, 2020
First Posted
October 5, 2020
Study Start
October 1, 2020
Primary Completion
October 1, 2021
Study Completion
October 1, 2021
Last Updated
October 10, 2022
Record last verified: 2022-10